KemPharm, Inc. to Present at Biotech Showcase™ 2013

Jan 02, 2013, 15:49 ET from KemPharm, Inc.

NORTH LIBERTY, Iowa, Jan. 2, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Biotech Showcase™ 2013 Conference being held in San Francisco January 7-9, 2013. 

Among the topics to be discussed, Dr. Mickle will provide an overview of KP201 the company's opioid-based drug candidate in development for the treatment of acute moderate to moderately severe pain that may deliver unique patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC).

Details of KemPharm's presentation are as follows:


Biotech Showcase 2013 Conference


Monday, January 7, 2013


4:00 pm, PST


Track A: Hearst - Parc 55 Wyndham San Francisco Union Square Hotel

Co-produced by EBD Group and Demy-Colton Life Science Advisors, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.  Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.

About KemPharm
KemPharm is focused on the discovery and development of NCEs to treat serious medical conditions through its proprietary and broadly applicable LAT prodrug approach.  KemPharm utilizes its LAT prodrug technology to generate improved versions of FDA approved drugs.  KemPharm's business strategy includes seeking strategic development partners following rapid clinical proof-of-concept demonstration in a Phase 1 trial.  KemPharm also plans to explore discovery stage alliances with industry leaders, leveraging its prodrug know-how and LAT technology.  KemPharm is primarily focused on developing candidates for pain and other central nervous system disorders.

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle

Jason Rando / Claire Sojda


Tiberend Strategic Advisors, Inc.


SOURCE KemPharm, Inc.